

1           **Antimicrobial effect of sulconazole in combination with glucose/trehalose against**  
2           **carbapenem-resistant hypervirulent *Klebsiella pneumoniae* persists**

3

4           Miaomiao Xie<sup>1,2</sup>, Kaichao Chen<sup>1,2</sup>, Heng Heng<sup>1,3</sup>, Edward Wai-Chi Chan<sup>1</sup>, Sheng Chen<sup>1,2\*</sup>

5

6           <sup>1</sup> State Key Laboratory of Chemical Biology and Drug Discovery and Department of Food  
7           Science and Nutrition, The Hong Kong Polytechnic University, Hong Kong, China.

8           <sup>2</sup> Shenzhen Key Laboratory for Food Biological Safety Control, Food Safety and Technology  
9           Research Centre, The Hong Kong PolyU Shenzhen Research Institute, Shenzhen, China.

10          <sup>3</sup> Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary  
11          Medicine and Life Sciences, City University of Hong Kong, Hong Kong, China.

12

13          \* Corresponding author: Sheng Chen, E-mail: sheng.chen@polyu.edu.hk, State Key Laboratory  
14          of Chemical Biology and Drug Discovery and Department of Food Science and Nutrition, The  
15          Hong Kong Polytechnic University, Hong Kong, China.

16

17 **Abstract**

18 The emergence and rapid dissemination of carbapenem-resistant hypervirulent *Klebsiella*  
19 *pneumoniae* (CR-hvKP) pose a serious threat to public health. Antibiotic treatment failure of *K.*  
20 *pneumoniae* infections has been largely attributed to acquisition of antibiotic resistance and  
21 bacterial biofilm caused by the presence of antibiotic persisters. There is an urgent need for novel  
22 antimicrobial agents or therapy strategies to manage infections caused by these notorious  
23 pathogens. In this study, we screened a collection of compounds that can dissipate bacterial  
24 proton motive force (PMF) and intermediate metabolites that can suppress antibiotic tolerance,  
25 and identified an antifungal drug sulconazole which can act in combination with glucose or  
26 trehalose to exert strong antibacterial effect against starvation-induced CR-hvKP persisters.  
27 Investigation of underlying mechanisms showed that sulconazole alone caused dissipation of  
28 transmembrane PMF, and sulconazole used in combination with glucose or trehalose could  
29 significantly inhibit the efflux activity, reduce NADH and ATP levels, and cause intracellular  
30 accumulation of reactive oxygen species (ROS) in CR-hvKP persisters, eventually resulting in  
31 bacterial cell death. These findings suggest that the sulconazole and glucose/trehalose  
32 combination is highly effective in eradicating multidrug-resistant and hypervirulent *K.*  
33 *pneumoniae* persisters, and may be used in development of a feasible strategy for treatment of  
34 chronic and recurrent *K. pneumoniae* infections.

35 **Keywords:** Carbapenem-resistant hypervirulent *Klebsiella pneumoniae*, persisters,  
36 antimicrobial effect, sulconazole, glucose, trehalose

## 38 **1. Introduction**

39 Persisters are a subpopulation of susceptible bacteria which can survive lethal dosages of  
40 antibiotics because of their inactive physiological state (Lewis, 2010). Unlike antibiotic resistant  
41 strains which contain genetic modifications, persisters are genetically identical to the susceptible  
42 cells, exhibit the same minimal inhibitory concentration values but a different drug susceptibility  
43 phenotype in which they are tolerant to antibiotics at concentrations that would otherwise be  
44 lethal (Brauner et al., 2016). Several factors appear to induce the formation of persisters. First,  
45 persisters exist independently in the presence of antibiotics and other environmental signals  
46 (Helaine and Kugelberg, 2014). In addition, a variety of other environmental factors have been  
47 found to trigger persister formation such as starvation (Bernier et al., 2013), carbon source  
48 transitions (Amato et al., 2013), quorum sensing (Möker et al., 2010), host macrophages (Helaine  
49 et al., 2014) and antibiotics (Dörr et al., 2010). Furthermore, various mechanisms involving the  
50 toxin-antitoxin modules (Harms et al., 2016), respiration and energy production (Shan et al.,  
51 2017), efflux pumps (Pu et al., 2016) and drug target inactivation (McKay and Portnoy, 2015)  
52 can induce persister formation. Eradication of persisters with antibiotics is currently a major  
53 challenge since traditional antibiotics are mainly effective against actively growing bacteria only.  
54 Strategies to eradicate persisters are mainly categorized into three types, including killing  
55 persisters in the dormant state, resensitizing persisters to traditional antimicrobial agents, and  
56 avoiding formation of persisters (Wood, 2016). Persisters have been demonstrated to be rapidly  
57 activated by glycolysis intermediates and sugars, in which the resultant regrowing cells are  
58 susceptible to aminoglycoside (Allison et al., 2011). In addition, treatment with a combination  
59 of antibiotics is considered an effective way to eliminate persisters. For instance, polymyxin B

60 when used in combination with meropenem was recently demonstrated to successfully eradicate  
61 persisters from *Acinetobacter baumannii* (Gallo et al., 2017).

62  
63 To date, persisters are found to be ubiquitous among different bacterial species and have been  
64 well investigated in major pathogens such as *Escherichia coli* (Shan et al., 2017), *Staphylococcus*  
65 *aureus* (Conlon et al., 2016) and *Mycobacterium tuberculosis* (Vilchèze et al., 2017). Studies in  
66 persisters have been rarely reported in *Klebsiella pneumoniae*, which is one of the important  
67 hospital pathogens of increasing clinical concern and is often found in biofilm-related chronic  
68 and recurrent infections. Bacterial biofilm is considered as another important cause of therapy  
69 failure of *K. pneumoniae* due to the existence of antibiotic tolerant persisters that frequently  
70 result in persistent infections (Vuotto et al., 2014). Persisters are responsible for antibiotic  
71 tolerance, biofilms and recurrent infections in various pathogens such as *K. pneumoniae*, which  
72 generates high levels of tolerant persisters to survive under treatment by a variety of high  
73 concentrations of bactericidal antibiotics (Ren et al., 2015; Michiels et al., 2016; Li et al., 2018)  
74 and formation of persister is prevalent in clinical *K. pneumoniae* strains (Li et al., 2018).  
75 Bacterial population is often exposed to sub-bactericidal concentrations of antibiotics during  
76 treatment or in clinical environments, which significantly increased persister formation in *K.*  
77 *pneumoniae* strains (Li et al., 2018), gravely threatening our ability to manage persistence  
78 infections. Carbapenem-resistant hypervirulent *Klebsiella pneumoniae* (CR-hvKP) is a type of  
79 *K. pneumoniae* that expresses both carbapenem resistance and hypervirulence phenotypes,  
80 causing life-threatening community-acquired and nosocomial infections that cannot be cured by  
81 almost all currently available antibiotics. In addition, CR-hvKP strains also express multidrug

82 tolerance, which is responsible for these biofilm-related chronic *K. pneumoniae* infections.  
83 Therefore, development of novel antimicrobial agents or therapy strategies for the eradication of  
84 CR-hvKP persisters is increasingly needed. Sulconazole is an imidazole derivative with broad-  
85 spectrum antifungal activity and has been commonly used to treat skin fungal infections,  
86 including dermatophyte infections, pityriasis versicolor and candidiasis (Benfield and Stephen,  
87 1988). Sulconazole was also found to exhibit antimicrobial activity against the multidrug-  
88 resistant *Salmonella typhimurium* (Preethi et al., 2016), in which the antibacterial activity may  
89 be due to the inhibition of DNA gyrase and topoisomerase (Tanitame et al., 2004). In this study,  
90 we demonstrated that sulconazole used in combination with glucose or trehalose exhibited potent  
91 antimicrobial effect against starvation-induced CR-hvKP persisters. The bactericidal effect of  
92 sulconazole in combination with glucose or trehalose against CR-hvKP persisters was evaluated  
93 and the underlying mechanisms were explored.

94

95 **2. Materials and methods**

96 **2.1. Bacterial strains and drugs**

97 CR-hvKP strain HvKP2 used in this study was isolated from patient in our previous study (Gu  
98 et al., 2018). Briefly, CR-hvKP isolate HvKP2 was resistant to carbapenems, cephalosporins,  
99 quinolones and aminoglycoside but remained susceptible to polymyxins and tigecycline. ST11  
100 K47 CR-hvKP strain HvKP2 carried a pLVPK-like virulence plasmid conferring the  
101 hypervirulence phenotype. Sulconazole nitrate salt (CAS no. 61318-91-0), glucose (CAS no. 50-  
102 99-7) and trehalose (CAS no. 6138-23-4) were purchased from Sigma-Aldrich (USA).

103

104 **2.2. Time-dependent killing assay**

105 To generate a tolerant population (Wang et al., 2022), overnight culture of CR-hvKP isolate was  
106 100-fold diluted into fresh Luria-Bertani (LB) broth and incubated for about 2h to reach the  
107 exponential phase. Bacterial culture was then washed twice and resuspended in saline (0.85%  
108 NaCl), followed by incubation at 37°C for 24h to create starvation stress. After starvation for  
109 24h, bacterial culture was treated with sulconazole, glucose, or different combinations at 37°C;  
110 bacterial culture resuspended in saline was included as a control group. Viable bacterial counts  
111 were determined at 0h, 24h, 48h, 72h, and 96h by serial dilution. Killing curves were depicted  
112 by plotting viable counts against incubation time using GraphPad Prism 8 (San Diego, CA).

113

114 **2.3. Membrane potential assay**

115 The ability of sulconazole, glucose or combinations to induce dissipation of membrane potential  
116 in CR-hvKP strain was evaluated using a voltage-sensitive dye, 3,3-dipropyl-thiadicarbocyanine

117 [DiSC3(5)] (Hamamoto et al., 2015). CR-hvKP strain subjected to 24h starvation was washed  
118 and resuspended in PBS supplemented with 0.1M KCl to a final concentration of OD<sub>600</sub> of 0.2.  
119 Bacterial suspension was then incubated with 1μM DiSC3(5) for 15min in the dark, followed by  
120 treatment with sulconazole, glucose or different combinations of the two compounds; bacterial  
121 suspension without treatment was included as a control group. Valinomycin (1μg/mL) was  
122 included as a positive control. Fluorescence intensity was monitored for 10min using a  
123 SpectraMax iD3 multimode microplate reader with excitation wavelength at 610nm and  
124 emission wavelength at 660nm.

125 Compounds that dissipated PMF were screened from a drug library using the membrane potential  
126 assay as mentioned above. 2μg/mL valinomycin was included as a positive control. A compound  
127 caused a fluorescence level similar to or higher than that of 2μg/mL valinomycin was considered  
128 as a PMF dissipator. Screening of intermediate metabolites that suppressed starvation-induced  
129 antibiotic tolerance was performed by using a phenotype microarray (PM1 - PM5 microplates,  
130 Biolog) as previously reported (Wang et al., 2020).

131

#### 132 **2.4. NADH and ATP measurements**

133 CR-hvKP strain subjected to 24h starvation was then treated with sulconazole, glucose or various  
134 combinations at 37°C for 24h and bacterial culture resuspended in saline was included as a  
135 control group, followed by washed and resuspended in cold PBS to a final concentration of OD<sub>600</sub>  
136 of 0.2. The concentration of NADH was determined using an EnzyChrom NAD/NADH Assay  
137 Kit (BioAssay Systems). Briefly, bacterial cells (10<sup>8</sup> CFU) were homogenized with 100μL  
138 NADH extraction buffer and incubated at 60°C for 5min. Then, 20μL Assay Buffer and 100μL

139 opposite extraction buffer were added to neutralize the extracts. Samples were briefly vortexed  
140 and centrifuged at 14,000rpm for 5min. Next, 40 $\mu$ L supernatant and 80 $\mu$ L working reagent were  
141 quickly added into each well of a clear flat-bottom 96-well plate. Absorbance was measured at  
142 0min and after a 15min incubation at 565nm. NADH concentration was determined from a  
143 standard calibration curve depicting the relationship between the concentration of NADH and  
144 optical density (OD<sub>565</sub>). Bacterial culture subjected to 24h starvation was then treated with  
145 sulconazole, glucose or different combinations for 30min and bacterial culture resuspended in  
146 saline was included as a control group, intracellular ATP level was determined with an ATP  
147 Determination Kit (Invitrogen). Results were presented as mean and standard deviation of data  
148 of three independent experiments.

149

## 150 **2.5. Assessment of efflux inhibitory activity**

151 The effect of sulconazole, glucose and different combinations on efflux activities in strain  
152 HvKP2 was assessed with a dye Nile Red as previously described (Reens et al., 2018). Briefly,  
153 bacterial culture subjected to 24h starvation was treated with sulconazole, glucose or different  
154 combinations for 24h, and bacterial culture resuspended in saline was included as a control group.  
155 Then, bacterial culture was adjusted to OD<sub>600</sub> at 0.2 and stained with 5 $\mu$ M Nile Red for 3 hours  
156 at 37°C. After staining, bacterial culture was washed and resuspended in PBS supplemented with  
157 1mM MgCl<sub>2</sub>. Fluorescence intensity was monitored for 3min using 96-well black plate with  
158 excitation wavelength at 552nm and emission wavelength at 636nm, after which suspension was  
159 triggered with 50mM glucose and fluorescence intensity was then monitored for another 10min.  
160 The addition of 50mM glucose was used to energize the efflux pump and trigger the efflux of

161 Nile Red. After treatment with sulconazole, glucose or different combinations for 24h, followed  
162 by Nile Red staining and addition of 50mM glucose, bacterial culture was observed with a Nikon  
163 Eclipse Ti2 Microscope (Nikon, Japan) and fluorescence images were captured.

164

## 165 **2.6. Intracellular ROS accumulation**

166 To assess the level of intracellular ROS accumulation in HvKP2 persisters upon treatment with  
167 sulconazole, glucose and different combinations, DCF-DA assay was conducted as previously  
168 described (Dridi et al., 2015). Briefly, bacterial cultures subjected to 24h starvation were  
169 challenged with sulconazole, glucose or different combinations for 4h, and bacterial culture  
170 resuspended in saline was included as a control group. Bacterial cultures were then washed once  
171 and resuspended with warm PBS, followed by staining with 10 $\mu$ M DCF-DA for 30min. After  
172 staining, cultures were washed and resuspended with warm PBS. Fluorescence intensity was  
173 determined with excitation wavelength at 485nm and emission wavelength at 535nm. Viable  
174 counts in bacterial culture were determined by plating serial dilutions on LB agar. The level of  
175 intracellular ROS accumulation was depicted as fluorescence intensity normalized to viable  
176 bacterial counts.

177

## 178 **2.7. RNA sequencing and differential expression analysis**

179 Bacterial culture subjected to 24h starvation was then treated with 10 $\mu$ g/mL sulconazole, 2mM  
180 glucose, or combinations of 10 $\mu$ g/mL sulconazole and 2mM glucose at 37°C for 24h, and  
181 bacterial culture resuspended in saline was included as a control group. Total RNA was extracted  
182 by RNeasy Protect Bacteria Mini Kit (Qiagen, Germany), followed by DNase treatment using

183 Turbo DNA free kit (Invitrogen). RNA samples were then sent to Novogene Bioinformatic  
184 Technology for transcriptome sequencing. Genome of HvKP2 was used as the reference and  
185 genes were annotated by eggNOG-mapper (Cantalapiedra et al., 2021). Reads were mapped to  
186 the reference genome by Hisat2 (Kim et al., 2019). Quantification process was performed with  
187 featureCounts (Liao et al., 2014). A highly variable gene was defined as one of the top 500  
188 variable genes between conditions with  $|\log_2 \text{fold change}| > 1.5$ . Gene ontology (GO) analysis  
189 was used to classify the high variable genes with clusterProfile (Wu et al., 2021). RNA  
190 sequencing data has been deposited into the NCBI database under the accession number  
191 PRJNA1065810.

192

## 193 **2.8. Statistical analyses**

194 Statistical analyses were carried out by unpaired students' *t* test. Data was processed and  
195 presented by GraphPad Prism 8.

196

197 **3. Results**

198 **3.1. Screening of specific compounds that dissipated PMF and intermediate metabolites**  
199 **that suppressed starvation-induced antibiotic tolerance**

200 We set out to identify specific PMF dissipators from a drug library through a fluorescence-based  
201 high-throughput screening using a dye DiSC3(5), and identify specific intermediate metabolites  
202 that could suppress starvation-induced antibiotic tolerance in the presence of antibiotic through  
203 a phenotype microarray screening (PM1-PM5 microplates). Particularly, the screening identified  
204 11 compounds (including benzethonium chloride, cetylpyridinium chloride, alexidine HCl,  
205 econazole, miconazole nitrate, sulconazole nitrate, dronedarone HCl, clomifene citrate,  
206 otilonium bromide, cyclosporine and carbonyl cyanide m-chlorophenylhydrazone (CCCP)) that  
207 specifically dissipated bacterial PMF and 6 intermediate metabolites (including glucose, fructose,  
208 trehalose, mannitose, maltose and maltotriose) that could specifically suppress starvation-  
209 induced antibiotic tolerance. We then combined the two classes of compounds to test their  
210 antimicrobial effects against starvation-induced tolerant CR-hvKP population and demonstrated  
211 that sulconazole, when used in combination with glucose or trehalose, exerted strong  
212 antibacterial effect to eradicate CR-hvKP persisters (Supplementary Fig S1).

213  
214 **3.2. Sulconazole in combination with glucose/trehalose kills starvation-induced CR-hvKP**  
215 **persisters**

216 To evaluate the antimicrobial effect of the sulconazole and glucose/trehalose combination, time-  
217 dependent killing assays were conducted on starvation-induced CR-hvKP persisters. Treatment  
218 with 10µg/mL sulconazole alone for 96h could not effectively eradicate the tolerant HvKP2

219 population, while treatment with 4mM glucose alone caused a slight reduction in the bacterial  
220 population size. However, upon combined treatment of 5 $\mu$ g/mL sulconazole and 4mM glucose,  
221 HvKP2 persisters were completely eradicated at 96h (Fig 1a). Complete eradication of HvKP2  
222 persisters was also achieved at 72h upon treatment with a combination of 10 $\mu$ g/mL sulconazole  
223 and 4mM glucose (Fig 1b). Similar bactericidal effect was also observed upon treatment with a  
224 sulconazole/trehalose combination (Fig 1c, 1d), in which complete eradication of tolerant  
225 HvKP2 population can be achieved at 72h upon combined treatment with 10 $\mu$ g/mL sulconazole  
226 and 1mM trehalose, and even at 48h upon treatment with 10 $\mu$ g/mL sulconazole in combination  
227 with 4mM trehalose (Fig 1d). These results suggested that sulconazole, when used in  
228 combination with glucose or trehalose, exhibited strong bactericidal effect against starvation-  
229 induced CR-hvKP persisters. Sulconazole was also found to exhibit more effective killing  
230 against starvation-induced HvKP2 persisters than meropenem (40 $\mu$ g/mL) when in combination  
231 with 1mM glucose/trehalose (Supplementary Fig S2 a, b). In addition, we further evaluated the  
232 antimicrobial effect of sulconazole in combination with glucose against more clinical pathogens  
233 including carbapenem-resistant *K. pneumoniae* strains EH62 and HKU20 (Supplementary Fig  
234 S2 c, d), carbapenem-resistant *Escherichia coli* CL4 (Supplementary Fig S2 e) and carbapenem-  
235 resistant *Acinetobacter baumannii* CPC35 (Supplementary Fig S2 f) and got similar results.

236

### 237 **3.3. Sulconazole and glucose/trehalose combination caused dissipation of membrane PMF**

238 Treatment with sulconazole caused rapid dissipation of membrane potential in HvKP2 persisters  
239 in a dose-dependent manner with a level much higher than that caused by valinomycin (Fig 2a),  
240 while glucose and trehalose could not cause dissipation of membrane potential (Fig 2b, 2c).

241 However, combined treatment of 10µg/mL sulconazole with glucose caused a slight increase in  
242 membrane potential, which was similar to the level caused by 1µg/mL valinomycin but lower  
243 than that recorded for treatment of 10µg/mL sulconazole alone (Fig 2d). Combined treatment of  
244 10µg/mL sulconazole with trehalose caused a relatively high level of membrane potential  
245 dissipation when compared to treatment with 10µg/mL sulconazole and glucose combination,  
246 the level of which was similar to that recorded during treatment with 10µg/mL sulconazole alone  
247 (Fig 2e). The membrane PMF dissipation caused by the drug combination was not as obvious as  
248 that caused by sulconazole alone, which may be because the killing effect of glucose on persisters  
249 is through different mechanisms from PMF dissipation. The addition of glucose may provide  
250 additional energy sources for the bacteria to generate more proton through increased metabolic  
251 activities, which in turn render the PMF dissipation effect caused by sulconazole less obvious.  
252 Further experiments including metabolic activity relating assays are needed to verify this  
253 hypothesis.

254

#### 255 **3.4. Sulconazole and glucose/trehalose combination caused inhibition of efflux activity**

256 Nile red efflux test was performed to investigate the effect of the sulconazole and  
257 glucose/trehalose combination on the efflux activities in starvation-induced HvKP2 persisters.  
258 Nile red is an efflux pump substrate which would become strongly fluorescent upon partitioning  
259 into the bacterial membrane and could be immediately pumped out. Treatment with 10µg/mL  
260 sulconazole alone caused moderate decrease in export of Nile red, while treatment of 10µg/mL  
261 sulconazole in combination with 4mM glucose resulted in significant reduction in export of Nile  
262 red (Fig 3a, 3c). Inhibition of efflux activities was also observed when starvation-induced HvKP2

263 persisters were challenged with the sulconazole and trehalose combination (Fig 3b, 3d).

264

### 265 **3.5. Sulconazole and glucose/trehalose combination reduced in intracellular NADH and** 266 **ATP level**

267 ATP and NADH play important roles in the growth and survival of living organisms in diverse  
268 environments (Hara and Kondo, 2015; Bilan and Belousov, 2016). The generation of ATP is also  
269 the most relevant process to membrane potential, which depends on the PMF generated by  
270 electron transport chain (Hards and Cook, 2018; Xia et al., 2021). Treatment with sulconazole in  
271 combination with glucose or trehalose resulted in a significant decrease in intracellular NADH  
272 level when compared to untreated group and these treated with sulconazole alone (Fig 4a, 4b).  
273 In addition, intracellular ATP level also significantly decreased upon exposure to the sulconazole  
274 and glucose/trehalose combination (Fig 4c, 4d), suggesting that treatment with sulconazole in  
275 combination with glucose or trehalose resulted in reduction in the intracellular NADH level and  
276 the ability to synthesize ATP, thereby affecting energy supply in HvKP2 persisters.

277

### 278 **3.6. Sulconazole and glucose/trehalose combination led to intracellular ROS accumulation**

279 Accumulation of ROS in bacteria can trigger growth arrest or cell death through damaging DNA,  
280 RNA, proteins and membrane lipids (Wang et al., 2010). Destruction of membrane homeostasis  
281 is always due to ROS accumulation which causes increase in membrane permeability and  
282 damages when the level exceeds the antioxidant limit of cellular systems (Yang et al., 2022). A  
283 previous study reported that PMF dissipation was also associated with overproduction of ROS  
284 (Deng et al., 2020). Intracellular ROS level in HvKP2 persisters was determined and results

285 demonstrated that slightly higher level of ROS accumulation in HvKP2 persisters was induced  
286 by combined treatment of sulconazole and glucose/trehalose when compared to sulconazole,  
287 glucose or trehalose alone (Fig 4e, 4f), indicating that sulconazole, when used in combination  
288 with glucose or trehalose, could potentiate the oxidative damage of bacteria caused by ROS  
289 accumulation.

### 291 **3.7. Sulconazole and glucose combination led to changes of metabolism in CR-hvKP** 292 **persisters**

293 To further investigate the mechanisms underlying the bactericidal effect of the sulconazole and  
294 glucose combination, transcriptome analyses were performed on HvKP2 persisters upon  
295 exposure to sulconazole and glucose alone or in combination. GO enrichment analysis within  
296 the biological process showed that these differentially expressed genes recorded upon  
297 comparison between treatment with sulconazole in combination with glucose and the untreated  
298 control include those involved in carboxylic acid catabolism and energy production by oxidation  
299 and cellular respiration (Fig 5a). When HvKP2 persisters were exposed to sulconazole in  
300 combination with glucose, genes associated with oxidative phosphorylation including those  
301 encoding ATP synthase, NADH-quinone oxidoreductase and cytochrome oxidase were  
302 remarkably downregulated (Fig 5b). As mentioned, inhibition of the oxidative phosphorylation  
303 process and electron transfer chain activities is always due to intracellular ROS accumulation,  
304 which may result in bacterial cell death. In this work, genes involved in tricarboxylic acid (TCA)  
305 cycle, glycolysis and fatty acid oxidation were also found to be significantly downregulated (Fig  
306 5b), indicating that substantial changes in bacterial metabolic levels occurred. A subset of

307 differently expressed genes involved in ATP synthesis, NADH production and TCA cycle will  
308 be selected for further validation using quantitative real-time PCR.  
309

#### 310 **4. Discussion**

311 Persisters are rare phenotypic variants that exist within a susceptible isogenic subpopulation in  
312 all bacterial species and are able to tolerate lethal dosage of antibiotics (Lewis, 2007). Antibiotic  
313 tolerance is currently a significant healthcare issue, as persisters constitute an important reservoir  
314 of cells that may subsequently emerge as drug-resistant mutants (Barrett et al., 2019; Windels et  
315 al., 2019) and cause biofilm-related recurrent infections (Lewis, 2007). Mechanisms underlying  
316 persisters formation, survival and recovery are complicated. Stochastic and deterministic  
317 mechanisms involved in different cellular processes can cause bacterial growth arrest; these  
318 processes, including activities of toxin/antitoxin modules (Schumacher et al., 2009) and stringent  
319 response (Amato et al., 2013), may lead to tolerance formation and hence emergence of persisters.  
320 Although bacterial growth arrest and dormancy are the most common mechanisms that mediate  
321 persister formation, various lines of evidence suggest that persisters may also exhibit diverse  
322 physiological activities including those of the active electron transport chains (Orman and  
323 Brynildsen, 2015), ATP synthesis (Radzikowski et al., 2016), and synthesis and degradation of  
324 RNAs (Mok et al., 2015). Persisters have been described in *K. pneumoniae* in recent years (Ren  
325 et al., 2015; Michiels et al., 2016; Li et al., 2018). Given that *K. pneumoniae* is a major source  
326 of bacterial antibiotic resistance-encoding genetic elements, and that antibiotic tolerance due to  
327 the presence of persisters is closely associated with development of antibiotic resistance (Cohen  
328 et al., 2013), further study into mechanisms underlying persister formation in this bacterial  
329 species is necessary. In addition, recalcitrant infections related to *K. pneumoniae* may also be  
330 attributed to the fact that persisters escape or tolerate the host immunity. Therefore, complete  
331 elimination of *K. pneumoniae* persisters needs to be achieved to prevent the chronic and recurrent

332 *K. pneumoniae* infections.

333

334 Cell membrane is an indispensable component for bacteria and a promising target for  
335 development of new antimicrobial therapeutics (Farha et al., 2013). Bacterial PMF is the  
336 electrochemical proton gradient across the membrane, which plays an important role in ATP  
337 synthesis (Farha et al., 2013). PMF is crucial for bacterial growth and survival under normal and  
338 stress conditions (Strahl and Hamoen, 2010). As the driving force for ATP biosynthesis, PMF  
339 supplies the necessary energy for numerous cellular processes; therefore, the dissipation of one  
340 or both of its components (electric potential  $\Delta\psi$  or transmembrane proton gradient  $\Delta\text{pH}$ ) will  
341 dismantle the cellular adenylate-based energy production system, resulting in bacterial cell death  
342 (Farha et al., 2013). However, PMF has been largely disregarded as a target for antimicrobial  
343 agents due to the concern of toxicity of PMF dissipators. Previous studies have demonstrated the  
344 potency of PMF inhibitors to eradicate bacterial persisters. Dissipating the PMF might be a  
345 promising antibacterial strategy against different bacterial species. Compounds that dissipated  
346 the PMF inhibited flagellar motility (Paul et al., 2008), which prevented invasion and swarming  
347 activity that finally result in biofilm formation (Nan et al., 2011). In addition, PMF-targeted  
348 compounds could effectively eradicate dormant bacteria responsible for persistent infections  
349 (Lewis, 2007). Dormant bacteria which already exhibit diminished cellular metabolism and a  
350 relatively low level of PMF (Hurdle et al., 2011) could therefore be more susceptible to PMF  
351 inhibitors. Thus, dissipators of PMF could find their utility as novel therapy strategies against  
352 these persistent infections. The compound sulconazole identified in this study can cause  
353 dissipation of transmembrane PMF in CR-hvKP persisters, which will become a promising

354 therapy option.

355

356 Metabolites have been previously reported to resensitize bacterial populations to different  
357 antibiotics through diverse mechanisms (Allison et al., 2011; Prax et al., 2016; Gutierrez et al.,  
358 2017). For instance, daptomycin was reported to exhibit enhanced bactericidal efficiency against  
359 *Staphylococcus aureus* persists in the presence of glucose (Prax et al., 2016). Addition of  
360 glucose can trigger the metabolism in *Vibrio cholerae* persists through generation of PMF and  
361 transforming their physiology to the growth status, thereby enhancing their susceptibility to  
362 ciprofloxacin (Paranjape and Shashidhar, 2020). Mannitol has been reported to resensitize  
363 *Pseudomonas aeruginosa* biofilm to aminoglycosides (Barraud et al., 2013). In addition,  
364 metabolites can sensitize the persister cells of *Escherichia coli*, *S. aureus* and *Mycobacterium*  
365 *tuberculosis* to quinolones through stimulation of carbon and respiration metabolism (Gutierrez  
366 et al., 2017). Specific metabolites have been demonstrated to be associated with varying degrees  
367 of killing of tolerant sub-population by stimulating PMF and increasing antibiotic uptake  
368 (Allison et al., 2011). The combination of sulconazole and glucose used in this study can  
369 eradicate persistent CR-hvKP strains through inhibition of efflux activity, suppression of ATP  
370 generation and accumulation of ROS in bacterial cells, resulting in bacterial death. Facilitating  
371 TCA cycle by glucose activation that subsequently enhanced PMF-dependent uptake of  
372 antibiotic also resulted in higher rate of bacterial cell death in multidrug-resistant *Edwardisiella*  
373 *tarda* (Peng et al., 2015). However, transcriptome analysis showed that the combination of  
374 sulconazole and glucose caused significant downregulation of genes involved in TCA cycle,  
375 glycolysis and fatty acid oxidation, resulting in substantial changes in bacterial metabolic levels.

376  
377 In this study, we identified several compounds that can dissipate the bacterial PMF, and  
378 intermediate metabolites that can suppress the antibiotic tolerance in the presence of antibiotic  
379 through high-throughput screenings of an FDA-approved drug library and the testing in  
380 Phenotype Microarrays. We demonstrated that the antifungal drug sulconazole could effectively  
381 eradicate starvation-induced tolerant CR-hvKP population when used in combination with  
382 glucose or trehalose. Investigation of the mechanisms underlying the bactericidal effect of  
383 sulconazole showed that this compound caused dissipation of transmembrane PMF, and when  
384 used in combination with glucose could significantly inhibit efflux activity, suppress intracellular  
385 NADH and ATP production, and cause intracellular accumulation of ROS in CR-hvKP strain,  
386 eventually resulting in bacterial cell death. The drug combination seems to affect a wide range  
387 of crucial membrane-bound metabolic processes, leading to a downregulation of ATP production,  
388 central carbon metabolism and transcription activities. This study has some limitations. The  
389 antimicrobial effect of sulconazole in combination with glucose/trehalose was only evaluated in  
390 limited bacterial strains, which should be tested in more bacterial strains and bacterial species to  
391 expand the application of this drug combination. Mechanisms underlying the bactericidal effect  
392 of these compounds need to be further explored, especially these relating to metabolic activity.

393  
394 **5. Conclusions**  
395 Here we assessed the antimicrobial effects of sulconazole when used in combination with  
396 glucose or trehalose against starvation-induced CR-hvKP persisters and explored the  
397 mechanisms underlying the bactericidal activity of these compounds. Sulconazole caused

398 dissipation of transmembrane PMF, and sulconazole used in combination with glucose  
399 significantly inhibited the efflux activity, reduced NADH and ATP levels, and caused  
400 intracellular ROS accumulation in CR-hvKP persisters, eventually resulting in bacterial cell  
401 death. Sulconazole is a Food and Drug Administration-approved broad-spectrum imidazole  
402 antifungal agent. Drug repositioning, the new application of existing clinically approved drugs,  
403 can significantly reduce the time and costs of the drug discovery and development process. This  
404 study effectively repositions sulconazole as an antibacterial candidate and provides strong  
405 experimental evidence for the clinical application of sulconazole in CR-hvKP infections.

406

#### 407 **Funding**

408 This work was supported by Theme-based Research Scheme (grant number: T11-104/22-R) and  
409 General Research Fund (grant numbers: 11100321, 11100922) of Research Grant Council of  
410 Hong Kong SAR.

411

#### 412 **Declaration of Competing Interest**

413 The authors declare no competing interests.

414

415 **Reference**

- 416 Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by  
417 aminoglycosides. *Nature* 2011;473(7346):216-220.
- 418 Amato SM, Orman MA, Brynildsen MP. Metabolic control of persister formation in *Escherichia coli*. *Molecular*  
419 *Cell* 2013;50(4):475-487.
- 420 Barraud N, Buson A, Jarolimek W, Rice SA. Mannitol enhances antibiotic sensitivity of persister bacteria in  
421 *Pseudomonas aeruginosa* biofilms. *PLoS One* 2013;8(12):e84220.
- 422 Barrett TC, Mok WW, Murawski AM, Brynildsen MP. Enhanced antibiotic resistance development from  
423 fluoroquinolone persisters after a single exposure to antibiotic. *Nature Communications* 2019;10(1):1-11.
- 424 Benfield P, Stephen P. Sulconazole: a review of its antimicrobial activity and therapeutic use in superficial  
425 dermatomycoses. *Drugs* 1988;35:143-153.
- 426 Bernier SP, Lebeaux D, DeFrancesco AS, Valomon A, Soubigou G, Coppée J-Y, Ghigo J-M, Beloin C.  
427 Starvation, together with the SOS response, mediates high biofilm-specific tolerance to the fluoroquinolone  
428 ofloxacin. *PLoS Genetics* 2013;9(1):e1003144.
- 429 Bilan DS, Belousov VV. Genetically encoded probes for NAD<sup>+</sup>/NADH monitoring. *Free Radical Biology and*  
430 *Medicine* 2016;100:32-42.
- 431 Brauner A, Fridman O, Gefen O, Balaban NQ. Distinguishing between resistance, tolerance and persistence  
432 to antibiotic treatment. *Nature Reviews Microbiology* 2016;14(5):320-330.
- 433 Cantalapiedra CP, Hernández-Plaza A, Letunic I, Bork P, Huerta-Cepas J. eggNOG-mapper v2: functional  
434 annotation, orthology assignments, and domain prediction at the metagenomic scale. *Molecular Biology and*  
435 *Evolution* 2021;38(12):5825-5829.
- 436 Cohen NR, Lobritz MA, Collins JJ. Microbial persistence and the road to drug resistance. *Cell Host & Microbe*  
437 2013;13(6):632-642.
- 438 Conlon BP, Rowe SE, Gandt AB, Nuxoll AS, Donegan NP, Zalis EA, Clair G, Adkins JN, Cheung AL, Lewis K.  
439 Persister formation in *Staphylococcus aureus* is associated with ATP depletion. *Nature Microbiology*  
440 2016;1(5):1-7.
- 441 Dörr T, Vulić M, Lewis K. Ciprofloxacin causes persister formation by inducing the TisB toxin in *Escherichia*  
442 *coli*. *PLoS Biology* 2010;8(2):e1000317.
- 443 Deng W, Fu T, Zhang Z, Jiang X, Xie J, Sun H, Hu P, Ren H, Zhou P, Liu Q. L-lysine potentiates aminoglycosides  
444 against *Acinetobacter baumannii* via regulation of proton motive force and antibiotics uptake. *Emerging*  
445 *Microbes & Infections* 2020;9(1):639-650.
- 446 Dridi B, Lupien A, Bergeron MG, Leprohon P, Ouellette M. Differences in antibiotic-induced oxidative stress  
447 responses between laboratory and clinical isolates of *Streptococcus pneumoniae*. *Antimicrobial Agents and*  
448 *Chemotherapy* 2015;59(9):5420-5426.
- 449 Farha MA, Verschoor CP, Bowdish D, Brown ED. Collapsing the proton motive force to identify synergistic  
450 combinations against *Staphylococcus aureus*. *Chemistry & Biology* 2013;20(9):1168-1178.
- 451 Gallo SW, Ferreira CAS, de Oliveira SD. Combination of polymyxin B and meropenem eradicates persister  
452 cells from *Acinetobacter baumannii* strains in exponential growth. *Journal of Medical Microbiology* 2017.
- 453 Gu D, Dong N, Zheng Z, Lin D, Huang M, Wang L, Chan EW-C, Shu L, Yu J, Zhang R. A fatal outbreak of ST11  
454 carbapenem-resistant hypervirulent *Klebsiella pneumoniae* in a Chinese hospital: a molecular  
455 epidemiological study. *The Lancet Infectious Diseases* 2018;18(1):37-46.
- 456 Gutierrez A, Jain S, Bhargava P, Hamblin M, Lobritz MA, Collins JJ. Understanding and sensitizing density-  
457 dependent persistence to quinolone antibiotics. *Molecular Cell* 2017;68(6):1147-1154. e3.
- 458 Hamamoto H, Urai M, Ishii K, Yasukawa J, Paudel A, Murai M, Kaji T, Kuranaga T, Hamase K, Katsu T. Lysocin

459 E is a new antibiotic that targets menaquinone in the bacterial membrane. *Nature Chemical Biology*  
460 2015;11(2):127-133.

461 Hara KYKondo A. ATP regulation in bioproduction. *Microbial Cell Factories* 2015;14(1):1-9.

462 Hards KCook GM. Targeting bacterial energetics to produce new antimicrobials. *Drug Resistance Updates*  
463 2018;36:1-12.

464 Harms A, Maisonneuve E, Gerdes K. Mechanisms of bacterial persistence during stress and antibiotic  
465 exposure. *Science* 2016;354(6318):aaf4268.

466 Helaine SKugelberg E. Bacterial persisters: formation, eradication, and experimental systems. *Trends in*  
467 *Microbiology* 2014;22(7):417-424.

468 Helaine S, Cheverton AM, Watson KG, Faure LM, Matthews SA, Holden DW. Internalization of *Salmonella* by  
469 macrophages induces formation of nonreplicating persisters. *Science* 2014;343(6167):204-208.

470 Hurdle JG, O'Neill AJ, Chopra I, Lee RE. Targeting bacterial membrane function: an underexploited mechanism  
471 for treating persistent infections. *Nature Reviews Microbiology* 2011;9(1):62-75.

472 Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with  
473 HISAT2 and HISAT-genotype. *Nature Biotechnology* 2019;37(8):907-915.

474 Lewis K. Persister cells, dormancy and infectious disease. *Nature Reviews Microbiology* 2007;5(1):48-56.

475 Lewis K. Persister cells. *Annual Review of Microbiology* 2010;64:357-372.

476 Li Y, Zhang L, Zhou Y, Zhang Z, Zhang X. Survival of bactericidal antibiotic treatment by tolerant persister  
477 cells of *Klebsiella pneumoniae*. *Journal of Medical Microbiology* 2018;67(3):273-281.

478 Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads  
479 to genomic features. *Bioinformatics* 2014;30(7):923-930.

480 McKay SLPortnoy DA. Ribosome hibernation facilitates tolerance of stationary-phase bacteria to  
481 aminoglycosides. *Antimicrobial Agents and Chemotherapy* 2015;59(11):6992-6999.

482 Michiels JE, Van den Bergh B, Verstraeten N, Fauvart M, Michiels J. In vitro emergence of high persistence  
483 upon periodic aminoglycoside challenge in the ESKAPE pathogens. *Antimicrobial Agents and Chemotherapy*  
484 2016;60(8):4630-4637.

485 Mok WW, Park JO, Rabinowitz JD, Brynildsen MP. RNA futile cycling in model persisters derived from MazF  
486 accumulation. *MBio* 2015;6(6):e01588-15.

487 Mo'ker N, Dean CR, Tao J. *Pseudomonas aeruginosa* increases formation of multidrug-tolerant persister  
488 cells in response to quorum-sensing signaling molecules. *Journal of Bacteriology* 2010;192(7):1946-1955.

489 Nan B, Chen J, Neu JC, Berry RM, Oster G, Zusman DR. Myxobacteria gliding motility requires cytoskeleton  
490 rotation powered by proton motive force. *Proceedings of the National Academy of Sciences*  
491 2011;108(6):2498-2503.

492 Orman MABrynildsen MP. Inhibition of stationary phase respiration impairs persister formation in *E. coli*.  
493 *Nature Communications* 2015;6(1):1-13.

494 Paranjape SSShashidhar R. Glucose sensitizes the stationary and persistent population of *Vibrio cholerae* to  
495 ciprofloxacin. *Archives of Microbiology* 2020;202(2):343-349.

496 Paul K, Erhardt M, Hirano T, Blair DF, Hughes KT. Energy source of flagellar type III secretion. *Nature*  
497 2008;451(7177):489-492.

498 Peng B, Su Y-b, Li H, Han Y, Guo C, Tian Y-m, Peng X-x. Exogenous alanine and/or glucose plus kanamycin  
499 kills antibiotic-resistant bacteria. *Cell Metabolism* 2015;21(2):249-262.

500 Prax M, Mechler L, Weidenmaier C, Bertram R. Glucose augments killing efficiency of daptomycin challenged  
501 *Staphylococcus aureus* persisters. *PLoS One* 2016;11(3):e0150907.

502 Preethi B, Shanthi V, Ramanathan K. Identification of potential therapeutics to conquer drug resistance in  
503 *Salmonella typhimurium*: drug repurposing strategy. *BioDrugs* 2016;30:593-605.

504 Pu Y, Zhao Z, Li Y, Zou J, Ma Q, Zhao Y, Ke Y, Zhu Y, Chen H, Baker MA. Enhanced efflux activity facilitates  
505 drug tolerance in dormant bacterial cells. *Molecular Cell* 2016;62(2):284-294.

506 Radzikowski JL, Vedelaar S, Siegel D, Ortega AD, Schmidt A, Heinemann M. Bacterial persistence is an active  
507  $\sigma^S$  stress response to metabolic flux limitation. *Molecular Systems Biology* 2016;12(9):882.

508 Reens AL, Crooks AL, Su C-C, Nagy TA, Reens DL, Podoll JD, Edwards ME, Yu EW, Detweiler CS. A cell-based  
509 infection assay identifies efflux pump modulators that reduce bacterial intracellular load. *PLoS Pathogens*  
510 2018;14(6):e1007115.

511 Ren H, He X, Zou X, Wang G, Li S, Wu Y. Gradual increase in antibiotic concentration affects persistence of  
512 *Klebsiella pneumoniae*. *Journal of Antimicrobial Chemotherapy* 2015;70(12):3267-3272.

513 Schumacher MA, Piro KM, Xu W, Hansen S, Lewis K, Brennan RG. Molecular mechanisms of HipA-mediated  
514 multidrug tolerance and its neutralization by HipB. *Science* 2009;323(5912):396-401.

515 Shan Y, Brown Gandt A, Rowe SE, Deisinger JP, Conlon BP, Lewis K. ATP-dependent persister formation in  
516 *Escherichia coli*. *MBio* 2017;8(1):e02267-16.

517 Strahl HH, Moen LW. Membrane potential is important for bacterial cell division. *Proceedings of the National*  
518 *Academy of Sciences* 2010;107(27):12281-12286.

519 Tanitame A, Oyamada Y, Ofuji K, Fujimoto M, Suzuki K, Ueda T, Terauchi H, Kawasaki M, Nagai K, Wachi M.  
520 Synthesis and antibacterial activity of novel and potent DNA gyrase inhibitors with azole ring. *Bioorganic &*  
521 *medicinal chemistry* 2004;12(21):5515-5524.

522 Vilchèze C, Hartman T, Weinrick B, Jain P, Weisbrod TR, Leung LW, Freundlich JS, Jacobs Jr WR. Enhanced  
523 respiration prevents drug tolerance and drug resistance in *Mycobacterium tuberculosis*. *Proceedings of the*  
524 *National Academy of Sciences* 2017;114(17):4495-4500.

525 Vuotto C, Longo F, Balice MP, Donelli G, Varaldo PE. Antibiotic resistance related to biofilm formation in  
526 *Klebsiella pneumoniae*. *Pathogens* 2014;3(3):743-758.

527 Wang M, Chan EWC, Yang C, Chen K, So P-k, Chen S. N-acetyl-D-glucosamine acts as adjuvant that re-  
528 sensitizes starvation-induced antibiotic-tolerant population of *E. coli* to  $\beta$ -lactam. *IScience* 2020;23(11).

529 Wang M, Chan EWC, Xu C, Chen K, Yang C, Chen S. Econazole as adjuvant to conventional antibiotics is able  
530 to eradicate starvation-induced tolerant bacteria by causing proton motive force dissipation. *Journal of*  
531 *Antimicrobial Chemotherapy* 2022;77(2):425-432.

532 Wang X, Zhao X, Malik M, Drlica K. Contribution of reactive oxygen species to pathways of quinolone-  
533 mediated bacterial cell death. *Journal of Antimicrobial Chemotherapy* 2010;65(3):520-524.

534 Windels EM, Michiels JE, Fauvart M, Wenseleers T, Van den Bergh B, Michiels J. Bacterial persistence promotes  
535 the evolution of antibiotic resistance by increasing survival and mutation rates. *The ISME Journal*  
536 2019;13(5):1239-1251.

537 Wood TK. Combatting bacterial persister cells. *Biotechnology and Bioengineering* 2016;113(3):476-483.


538 Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L. clusterProfiler 4.0: A universal  
539 enrichment tool for interpreting omics data. *The Innovation* 2021;2(3):100141.

540 Xia Y, Cebrián R, Xu C, Jong Ad, Wu W, Kuipers OP. Elucidating the mechanism by which synthetic helper  
541 peptides sensitize *Pseudomonas aeruginosa* to multiple antibiotics. *PLoS Pathogens* 2021;17(9):e1009909.


542 Yang X, Sun H, Maddili SK, Li S, Yang R-G, Zhou C-H. Dihydropyrimidinone imidazoles as unique structural  
543 antibacterial agents for drug-resistant gram-negative pathogens. *European Journal of Medicinal Chemistry*  
544 2022;232:114188.

545


546




548  
 549 Fig 1. Time-dependent killing assay of CR-hvKP strain HvKP2. (a) and (b) CR-hvKP strain  
 550 HvKP2 subjected to 24h starvation was treated with sulconazole, glucose or various  
 551 combinations of both compounds for 96h. (c) and (d) CR-hvKP strain HvKP2 subjected to 24h  
 552 starvation was treated with sulconazole, trehalose or various combinations of both compounds  
 553 for 96h. Results were presented as mean and SD of three independent experiments (Some error  
 554 bars cannot be observed due to the scale of the Y axis, which compress the error bars to the point  
 555 where they were not visible.). Sulcon, sulconazole.  
 556




557  
 558 Fig 2. Assessment of membrane potential in CR-hvKP strain HvKP2. Membrane potential was  
 559 determined in starvation-induced HvKP2 persisters upon treatment with sulconazole (a), glucose  
 560 (b), trehalose (c), sulconazole in combination with glucose (d), and sulconazole in combination  
 561 with trehalose (e). Fluorescent dye DiSC3(5) was used to determine the membrane potential, and  
 562 valinomycin was included as a positive control. Results were presented as mean and SD of three  
 563 independent experiments.  
 564



565  
 566 Fig 3. Inhibitory effect of sulconazole in combination with glucose or trehalose on efflux activity  
 567 in CR-hvKP persisters. Fluorescence intensity of Nile Red in HvKP2 upon treatment with the  
 568 sulconazole and glucose combination (a), and sulconazole in combination with trehalose (b).  
 569 Glucose (50mM) was added to bacterial suspension at 3min, and fluorescence intensity was  
 570 monitored for another 10min. (c) Microscopic images of HvKP2 persisters treated with  
 571 sulconazole, glucose or combinations, followed by Nile Red staining for 3h. (d) Microscopic  
 572 images of HvKP2 persisters treated with sulconazole, trehalose or different combinations,  
 573 followed by Nile Red staining for 3h. Results were presented as mean and SD of three  
 574 independent experiments (Some error bars cannot be observed due to the scale of the Y axis,  
 575 which compress the error bars to the point where they were not visible.)  
 576



577  
 578 Fig 4. NADH, ATP and ROS production in CR-hvKP persisters. Intracellular NADH level was  
 579 measured in HvKP2 persisters upon treatment with the sulconazole and glucose combination (a),  
 580 and sulconazole in combination with trehalose (b). \*\*, 0.001<P<0.01. Intracellular ATP levels  
 581 were measured upon treatment of sulconazole in combination with glucose (c), and sulconazole  
 582 in combination with trehalose (d) for 30min. \*\*\*, 0.0001<P<0.001; \*\*\*\*, P<0.0001. ROS  
 583 accumulation in HvKP2 persisters upon treatment of sulconazole in combination with glucose  
 584 (e), and sulconazole in combination with trehalose (f). Intracellular ROS accumulation was  
 585 depicted as the fluorescence intensity of ROS normalized to viable cell counts. \*, 0.01<P<0.05;  
 586 \*\*, 0.001<P<0.01. Results were presented as mean and standard deviation of three tests.  
 587



588  
 589 Fig 5. Transcriptome analysis of HvKP2 persists upon exposure to sulconazole or glucose  
 590 alone and in combination. (a) Gene Ontology (GO) enrichment analysis. Genes were annotated  
 591 in biological process, and the top 20 most enriched GO terms between treatment with the  
 592 sulconazole and glucose combination, and the untreated control, are shown. (b) Effect of glucose,  
 593 sulconazole alone or in combination on expression of genes involved in oxidative  
 594 phosphorylation and metabolism. Log<sub>2</sub>FC, Log<sub>2</sub> Fold Change.  
 595